Presentation is loading. Please wait.

Presentation is loading. Please wait.

Graphic presentation of growth differentiation factor-15 (GDF-15), von Willebrand factor (vWF), vascular endothelial growth factor (VEGF)-1 and angiopoietin-2.

Published byGiovanna Giuseppe Modified over 5 years ago

Similar presentations

Presentation on theme: "Graphic presentation of growth differentiation factor-15 (GDF-15), von Willebrand factor (vWF), vascular endothelial growth factor (VEGF)-1 and angiopoietin-2."— Presentation transcript:

1 Graphic presentation of growth differentiation factor-15 (GDF-15), von Willebrand factor (vWF), vascular endothelial growth factor (VEGF)-1 and angiopoietin-2 during exercise and recovery with high and moderate intensity in the heart transplant recipients, ... Graphic presentation of growth differentiation factor-15 (GDF-15), von Willebrand factor (vWF), vascular endothelial growth factor (VEGF)-1 and angiopoietin-2 during exercise and recovery with high and moderate intensity in the heart transplant recipients, with inserted P value for the analysis of variance interaction effect, exercise session×time. Level of significance: P value <0.1. HIT, high-intensity interval training; MICT, moderate-intensity continuous training. Marianne Yardley et al. Open Heart 2017;4:e000635 ©2017 by British Cardiovascular Society

Download ppt "Graphic presentation of growth differentiation factor-15 (GDF-15), von Willebrand factor (vWF), vascular endothelial growth factor (VEGF)-1 and angiopoietin-2."

Similar presentations

Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)

Age-related cumulative incidence for (A) serious adverse events (including death, heart failure admission, ventricular arrhythmia and cardiac transplant)
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Endothelial hyperpermeability after cardiac surgery with cardiopulmonary bypass as assessed using an in vitro bioassay for endothelial barrier function 

Endothelial hyperpermeability after cardiac surgery with cardiopulmonary bypass as assessed using an in vitro bioassay for endothelial barrier function 
Correlation between maximal workload as achieved during a physical exercise test (treadmill or bicycle; horizontal axis) and left superficial femoral artery.

Correlation between maximal workload as achieved during a physical exercise test (treadmill or bicycle; horizontal axis) and left superficial femoral artery.
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
Frequency counts of exercise intensities routinely prescribed in programmes (n=194) grouped by method/scale. Frequency counts of exercise intensities routinely.

Frequency counts of exercise intensities routinely prescribed in programmes (n=194) grouped by method/scale. Frequency counts of exercise intensities routinely.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
(A) Image of a stent that was damaged withdrawing it back into a Guideliner V2 after failing to cross the lesion. (A) Image of a stent that was damaged.

(A) Image of a stent that was damaged withdrawing it back into a Guideliner V2 after failing to cross the lesion. (A) Image of a stent that was damaged.
The Role of Endothelial Cell Injury in Thrombotic Microangiopathy

The Role of Endothelial Cell Injury in Thrombotic Microangiopathy
Comparison of the bronchoalveolar lavage fluid (BALF) levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients.

Comparison of the bronchoalveolar lavage fluid (BALF) levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients.
Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
George D Yancopoulos, Michael Klagsbrun, Judah Folkman  Cell 

George D Yancopoulos, Michael Klagsbrun, Judah Folkman  Cell 
(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.
Comparison of CMR and echocardiography in aortic regurgitation.

Comparison of CMR and echocardiography in aortic regurgitation.
Comparison of the serum levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients with idiopathic pulmonary.

Comparison of the serum levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients with idiopathic pulmonary.
Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.
Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.

Toray microarray analysis of the four groups of patients (A) and in patients with calcium score >100 (B). Toray microarray analysis of the four groups.
Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Similar presentations

Ads by Google